About UTILITY therapeutics
UTILITY therapeutics is a company based in Altrincham (United Kingdom) founded in 2017 by Peter Villadsen and Rasmus Kehler was acquired by Alembic Pharmaceuticals in July 2025.. UTILITY therapeutics has raised $2.52 million across 2 funding rounds from investors including Alembic Pharmaceuticals. The company has 7 employees as of December 31, 2023. UTILITY therapeutics offers products and services including Antibiotic Therapies and Product Pipeline. UTILITY therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Altrincham, United Kingdom
- Employees 7 as on 31 Dec, 2023
- Founders Peter Villadsen, Rasmus Kehler
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Utility Therapeutics Ltd
- Date of Incorporation 19 Dec, 2017
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.52 M (USD)
in 2 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
Jul 08, 2019
- Investors
-
Employee Count
7
as on Dec 31, 2023
-
Acquired by
Alembic Pharmaceuticals
(Jul 03, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UTILITY therapeutics
UTILITY therapeutics offers a comprehensive portfolio of products and services, including Antibiotic Therapies and Product Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops drugs to combat drug-resistant urinary tract infections
Advances novel treatments for UTIs and related infections
Unlock access to complete
Unlock access to complete
Funding Insights of UTILITY therapeutics
UTILITY therapeutics has successfully raised a total of $2.52M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.5 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $2.5M
-
First Round
First Round
(06 Feb 2018)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2019 | Amount | Seed - UTILITY therapeutics | Valuation |
investors |
|
| Feb, 2018 | Amount | Seed - UTILITY therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in UTILITY therapeutics
UTILITY therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Alembic Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer & supplier of generic pharmaceuticals
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by UTILITY therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - UTILITY therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Utility Therapeutics Comparisons
Competitors of UTILITY therapeutics
UTILITY therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Utility Therapeutics
Frequently Asked Questions about UTILITY therapeutics
When was UTILITY therapeutics founded?
UTILITY therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is UTILITY therapeutics located?
UTILITY therapeutics is headquartered in Altrincham, United Kingdom. It is registered at Altrincham, Greater Manchester, United Kingdom.
Who is the current CEO of UTILITY therapeutics?
Thomas Hadley is the current CEO of UTILITY therapeutics.
Is UTILITY therapeutics a funded company?
UTILITY therapeutics is a funded company, having raised a total of $2.52M across 2 funding rounds to date. The company's 1st funding round was a Seed of $23.9K, raised on Feb 06, 2018.
How many employees does UTILITY therapeutics have?
As of Dec 31, 2023, the latest employee count at UTILITY therapeutics is 7.
What does UTILITY therapeutics do?
Developer of antibiotics to treat urinary tract infections and multi-drug resistant infections. It offers Pivmecillinam is an aminopenicillin, which is a specific class of beta-lactam antibiotic and mecillinam (a member of the penicillin subgroup of the β-lactam antibiotic class), is an oral prodrug pivmecillinam for the treatment of urinary tract infections.
Who are the top competitors of UTILITY therapeutics?
UTILITY therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
What products or services does UTILITY therapeutics offer?
UTILITY therapeutics offers Antibiotic Therapies and Product Pipeline.
Who are UTILITY therapeutics's investors?
UTILITY therapeutics has 1 investor. Key investors include Alembic Pharmaceuticals.